T-1105

T-1105, a structural analogue of T-705, is a novel broad-spectrum viral polymerase inhibitor. T-1105 inhibits the polymerases of RNA viruses after being converted to ribonucleoside triphosphate (RTP) metabolite. T-1105 has antiviral activity against various RNA viruses. T-1105 can be formed by nicotinamide mononucleotide adenylyltransferase[1][2].

Product Specifications

CAS Number

[55321-99-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Flavivirus

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/t-1105.html

Concentration

10mM

Purity

99.74

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=NC=CN=C1O)N

Molecular Formula

C5H5N3O2

Molecular Weight

139.11

Precautions

H302, H315, H319, H335

References & Citations

[1]Huchting J, et al. Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir) . Antiviral Res. 2019 Jul;167:1-5.|[2]Furuta Y, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009 Jun;82 (3) :95-102.|[3]Johanna Huchting, et al. Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir) . Antiviral Res. 2019 Jul;167:1-5.|[4]Lei Cai, et al. Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication. Arch Virol. 2017 Sep;162 (9) :2847-2853. |[5]Hideki Tani, et al. Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus.|[6]Yousuke Furuta, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009 Jun;82 (3) :95-102.